Difference between revisions of "Dermatofibrosarcoma protuberans"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "'''dosing details in manuscript have been reviewed'''" to "'''dosing details in manuscript have been reviewed by our editors'''")
 
(5 intermediate revisions by 3 users not shown)
Line 12: Line 12:
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 
=Guidelines=
 
=Guidelines=
−
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.'''
+
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
−
==[https://www.nccn.org/ NCCN]==
+
==NCCN==
−
*[https://www.nccn.org/professionals/physician_gls/pdf/dfsp.pdf NCCN Guidelines - Dermatofibrosarcoma Protuberans (DFSP)]
+
*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1430 NCCN Guidelines - Dermatofibrosarcoma Protuberans (DFSP)]
−
 
+
**'''2014:''' Bichakjian et al. [https://doi.org/10.6004/jnccn.2014.0081 Dermatofibrosarcoma protuberans, version 1.2014] [https://pubmed.ncbi.nlm.nih.gov/24925197/ PubMed]
−
*'''2014:''' Bichakjian et al. [https://doi.org/10.6004/jnccn.2014.0081 Dermatofibrosarcoma protuberans, version 1.2014] [https://pubmed.ncbi.nlm.nih.gov/24925197/ PubMed]
+
**'''2012:''' Miller et al. [https://doi.org/10.6004/Jnccn.2012.0032 Dermatofibrosarcoma protuberans.] [https://pubmed.ncbi.nlm.nih.gov/22393193/ PubMed]
−
*'''2012:''' Miller et al. [https://doi.org/10.6004/Jnccn.2012.0032 Dermatofibrosarcoma protuberans.] [https://pubmed.ncbi.nlm.nih.gov/22393193/ PubMed]
+
**'''2007:''' Miller et al. [https://doi.org/10.6004/Jnccn.2007.0048 Dermatofibrosarcoma protuberans.] [https://pubmed.ncbi.nlm.nih.gov/17509257/ PubMed]
−
*'''2007:''' Miller et al. [https://doi.org/10.6004/Jnccn.2007.0048 Dermatofibrosarcoma protuberans.] [https://pubmed.ncbi.nlm.nih.gov/17509257/ PubMed]
+
**'''2004:''' Authors not listed. [https://doi.org/10.6004/Jnccn.2004.0006 Dermatofibrosarcoma protuberans. Clinical practice guidelines in oncology.] [https://pubmed.ncbi.nlm.nih.gov/19777697/ PubMed]
−
*'''2004:''' Unknown author. [https://doi.org/10.6004/Jnccn.2004.0006 Dermatofibrosarcoma protuberans. Clinical practice guidelines in oncology.] [https://pubmed.ncbi.nlm.nih.gov/19777697/ PubMed]
 
  
 
=All lines of therapy=
 
=All lines of therapy=
Line 58: Line 57:
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# '''EORTC 62027:''' Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; [[Study_Groups#SWOG|SWOG]]. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. [https://doi.org/10.1200/JCO.2009.25.7899 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20194851/ PubMed] [https://clinicaltrials.gov/study/NCT00085475 NCT00085475]
+
# '''EORTC 62027:''' Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; [[Study_Groups#SWOG|SWOG]]. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. [https://doi.org/10.1200/JCO.2009.25.7899 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20194851/ PubMed] [https://clinicaltrials.gov/study/NCT00085475 NCT00085475]
−
# '''SWOG S0345:''' Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; [[Study_Groups#SWOG|SWOG]]. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. [https://doi.org/10.1200/JCO.2009.25.7899 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20194851/ PubMed] [https://clinicaltrials.gov/study/NCT00084630 NCT00084630]
+
# '''SWOG S0345:''' Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; [[Study_Groups#SWOG|SWOG]]. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. [https://doi.org/10.1200/JCO.2009.25.7899 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20194851/ PubMed] [https://clinicaltrials.gov/study/NCT00084630 NCT00084630]
 
[[Category:Dermatofibrosarcoma protuberans regimens]]
 
[[Category:Dermatofibrosarcoma protuberans regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Soft tissue sarcomas]]
 
[[Category:Soft tissue sarcomas]]

Latest revision as of 12:21, 15 July 2024

Back to Top

Section editor
Elizabethdavis2.jpg
 Elizabeth J. Davis, MD
Vanderbilt University
Nashville, TN, USA

Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.

1 regimens on this page
2 variants on this page


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

NCCN

All lines of therapy

Imatinib monotherapy

Regimen variant #1, 400 mg/day

Study Dates of enrollment Evidence
Rutkowski et al. 2010 (SWOG S0345) 2005-2006 Phase 2, fewer than 20 pts

Targeted therapy

48-week course


Regimen variant #2, 800 mg/day

Study Dates of enrollment Evidence
Rutkowski et al. 2010 (EORTC 62027) 2004-2007 Phase 2, fewer than 20 pts (RT)

Targeted therapy

Continued indefinitely, unless complete (R0) surgical resection became possible

References

  1. EORTC 62027: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00085475
  2. SWOG S0345: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00084630
Retrieved from "https://hemonc.org/w/index.php?title=Dermatofibrosarcoma_protuberans&oldid=89566"